secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001193125-25-020831
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML
--------------------------------------------------------------------------------

- KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.
- NDA submission to FDA for ziftomenib in R/R NPM1-m AML on track for Q2 2025.
- Plans to initiate two Phase 3 frontline trials (KOMET-017) in 2H 2025 with dual-primary endpoints for potential accelerated and full approval.
- Multiple data presentations expected in 2025 across ziftomenib, KO-2806, and tipifarnib programs.
- Collaboration with Kyowa Kirin continues for commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/0001193125-25-020831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525020831/d886608d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-020831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer